<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176565</url>
  </required_header>
  <id_info>
    <org_study_id>1207M17921</org_study_id>
    <secondary_id>U01NS062091</secondary_id>
    <secondary_id>U01NS061861</secondary_id>
    <secondary_id>U01NS059041</secondary_id>
    <secondary_id>U01NS056975</secondary_id>
    <secondary_id>H23-4-3</secondary_id>
    <nct_id>NCT01176565</nct_id>
  </id_info>
  <brief_title>Antihypertensive Treatment of Acute Cerebral Hemorrhage-II</brief_title>
  <acronym>ATACH-II</acronym>
  <official_title>Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH)-II: A Phase III Randomized Multicenter Clinical Trial of Blood Pressure Reduction for Hypertension in Acute Intracerebral Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Neurocritical Care Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cerebral and Cardiovascular Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Japan Cardiovascular Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific aims of this study are to:

        1. Definitively determine the therapeutic benefit of the intensive treatment relative to
           the standard treatment in the proportion of patients with death and disability (mRS 4-6)
           at 3 months among subjects with ICH who are treated within 4.5 hours of symptom onset.

        2. Evaluate the therapeutic benefit of the intensive treatment relative to the standard
           treatment in the subjects' quality of life as measured by EuroQol at 3 months.

        3. Evaluate the therapeutic benefit of the intensive treatment relative to the standard
           treatment in the proportion of hematoma expansion (defined as increase from baseline
           hematoma volume of at least 33%) and in the change from baseline peri-hematoma volume at
           24 hours on the serial computed tomographic (CT) scans.

        4. Assess the safety of the intensive treatment relative to the standard treatment in the
           proportion of subjects with treatment-related serious adverse events (SAEs) within 72
           hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The report from a National Institute of Neurological Disorders and Stroke Workshop on
      priorities for clinical research in intracerebral hemorrhage (ICH) in December 2003
      recommended clinical trials for evaluation of blood pressure (BP) management in acute ICH as
      a leading priority. The Special Writing Group of the Stroke Council of the American Heart
      Association in 1999 and 2007 emphasized the need for clinical trials to ensure evidence-based
      treatment of acute hypertension in ICH. Consequently, we propose to conduct a five-year
      international, multicenter, open-labeled, randomized, controlled, Phase III trial to
      determine the efficacy of early, intensive antihypertensive treatment using intravenous
      nicardipine for acute hypertension in subjects with co-morbid hypertension and spontaneous
      supratentorial ICH. The primary hypothesis of this large, streamlined, focused trial is that
      the group treated with intensive BP reduction (systolic BP [SBP] of 140 mmHg or less -
      hereafter referred to as the intensive treatment) using intravenous nicardipine infusion for
      24 hours reduces the proportion of death and disability at 3 months by 10% or greater
      compared with the group treated with the standard BP reduction (SBP of 180 mmHg or less -
      hereafter referred to as the standard treatment) among patients with ICH treated within 4.5
      hours of symptom onset. The underlying mechanism for this expected beneficial effect of
      intensive treatment is mediated through reduction of the rate and magnitude of hematoma
      expansion observed in approximately 38% of patients with acute ICH. The trial will recruit a
      maximum of 1,280 subjects with ICH who meet the eligibility criteria. The primary outcome is
      the proportion of death and disability at 3 months defined by modified Rankin scale (mRS)
      score of 4 to 6. The proposed clinical trial is the natural extension of numerous case
      series, a subsequent pilot trial funded by the National Institutes of Health National
      Institute of Health (NIH), and a preliminary randomized controlled trial in this patient
      group funded by the Australian National Health and Medical Research Council, that have
      recently confirmed the safety and tolerability of both the regimen and goals of the
      antihypertensive treatment in acutely hypertensive patients with ICH proposed in the present
      trial. The proposed trial will have important public health implications by providing
      necessary information regarding the efficacy and safety of antihypertensive treatment of
      acute hypertension observed in up to 75% of the subjects with ICH. BP treatment represents a
      strategy that can be made widely available without the need of specialized equipment and
      personnel and therefore can make a major impact upon outcome in patients with ICH.
      Substantial reduction in morbidity and mortality appears possible if the estimates of
      treatment effect sizes from current pilot trials are accurate.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Planned interim analysis: no significant outcome differences between groups
  </why_stopped>
  <start_date type="Actual">May 15, 2011</start_date>
  <completion_date type="Actual">March 8, 2016</completion_date>
  <primary_completion_date type="Actual">December 21, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible patients are randomized 1:1 via computer-generated treatment assignment within 4.5 hours of neurological symptom onset to either standard or intensive SBP management using intravenous nicardipine hydrochloride as the primary BP control agent through 24 hours from randomization. Enrolled patients from both treatment arms are otherwise treated similarly after 24 hours, according to their medical needs. Standards of care management for spontaneous intracerebral hemorrhage published in the 2010 American Heart Association guidelines are incorporated in to the study protocol. All enrolled patients are followed through 90 days (± 14 days per protocol window; up to ± 30 days data is used) unless death or withdrawal occurs sooner. Primary analysis based on intent-to-treat (ITT) principles.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>The trial intervention is conducted open-label to avoid concealing clinically necessary patient blood pressure and intravenous drug administration information. Clinical data including SBP values are primarily taken from entries recorded in to the patient's official medical record by hospital staff and are independently monitor-verified. Assessors for the primary outcome (mRS) at 90 days are are unaware of the treatment assignment or in-hospital clinical course of the subjects assessed. De-identified imaging studies are coded independently of subject number so the central imaging reader is unaware of the treatment assignment, clinical findings, or time points of image acquisition for data recorded from imaging. The study (lead) principal investigator and leadership committee members are unable to associate the treatment assignment of subjects to their outcomes or adverse events for purposes of trial decision-making. Adverse events are adjudicated by an independent oversight committee.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Death or Disability According to Modified Rankin Scale Score at 90 Days (3 Months) From Randomization</measure>
    <time_frame>90 days (± 14 days per protocol window; up to ± 30 days data is used) from randomization</time_frame>
    <description>The primary outcome was death or disability, defined by modified Rankin scale (mRS) of 4-6 at 90 days following treatment. The modified Rankin Scale score ranges from 0, indicating no symptoms, to 6, indicating death. A score of 4 indicates moderately severe disability including the inability to walk or attend to one's own bodily needs. A score of 5 indicates severe disability; bedridden, incontinent, and requiring constant nursing care. To score a 3 or lower on the mRS, a person must at least be able to walk without the assistance of another person. We chose the mRS because of its high inter-observer reliability, superiority to other indices, and consistency with previous trials in patients with ICH. Reliability was further increased by use of a structured interview template and by requiring mRS assessors to pass a certification test. Persons conducting the 90-day mRS assessment were to be unaware of the treatment arm or clinical course of the patients they assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life at 90 Days Using EuroQol (EQ) Measures: EQ-5D (EuroQol Five Dimension), Consisting of Standardized EQ-5D-3L (EuroQol Five Dimension, Three-Level) Questionnaire and EQ VAS (EuroQol Visual Analog Scale) Scores</measure>
    <time_frame>90 days (± 14 days per protocol window; up to ± 30 days data is used) from randomization</time_frame>
    <description>Standardized scales developed by the EuroQol Research Foundation were used as a secondary outcome measure in addition to the mRS scale score. The EQ-5D is a simple, standardized non-disease-specific instrument for describing and valuating health-related quality of life. The EQ-5D-3L questionnaire consists of 5 questions in 5 different domains and allows for responses from 1 (the best outcome) to 3 (the worst outcome) in each of five categories (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Total scores range from 5 to 15, with lower scores indicating better quality of life and a higher score indicating a worse quality of life. A second component of EuroQol outcome measurements is a printed 20 cm visual analogue scale (EQ VAS) that appears somewhat like a thermometer, on which a score from 0 (worst imaginable health state or death) to 100 (best imaginable health state) is marked by the patient (or, when necessary, their proxy) with the scale in view.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematoma Expansion (Number of Patients With Hematoma Expansion of 33% or Greater Between the Baseline and 24 +/- 6 Hours Head CTs, as Measured by the Central Reader for Patients With Readable Scans for Both Time Points Submitted by Data Lock.)</measure>
    <time_frame>From the baseline head CT to the 24 +/- 6 hours from randomization head CT</time_frame>
    <description>Hematoma expansion as determined by serial CT scans: Hematoma expansion was defined as an increase in the volume of intraparenchymal hemorrhage of 33% or greater as measured by a central imaging analyst who was was unaware of the treatment assignments, clinical findings, and time points of image acquisition. The area of the hematoma was delineated by image analysis software with the use of density thresholds on each slice, followed by manual correction. To ensure accuracy and consistency of the readings, images were coded randomly and independently of subject numbers and manual correction was also done without awareness of treatment assignments, clinical findings, or time points of image acquisition. This data point is defined as being present (hematoma expansion of 33% or more was calculated between the baseline scan hematoma volume and the 24 +/- 6 hours hematoma volume measures at data analysis), meaning that hematoma expansion as defined must have occurred or it was not counted.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Neurological Deterioration Within 24 Hours, Defined by a Decrease of 2 or More Points on the GCS Score or an Increase of 4 or More Points on the NIHSS Score From Baseline, Not Related to Sedation or Hypnotic-agent Use and Sustained for at Least 8 Hours.</measure>
    <time_frame>From randomization through the 24-hour treatment period</time_frame>
    <description>Neurologic deterioration was measured using two scales. The Glasgow Coma Scale (GCS) score measures of level of consciousness in eye, motor, and verbal components. At least one point is given in each category. The scale ranges from 3 to 15, with 3 indicating deep unconsciousness and 15 indicating consciousness is not impaired. The National Institutes of Health Stroke Scale (NIHSS) quantifies neurologic deficits in 11 categories. Level of consciousness, horizontal eye movement, visual fields, facial palsy, movement in each limb, sensation, language &amp; speech, and extinction or inattention on one side of the body are tested. Scores range from 0 to 42, with 0 indicating normal function and higher scores indicating greater deficit severity. Neurological status was checked per ICU standards through 24 hours, recommended as hourly GCS and full assessment every 2 hours. NIHSS assessment at baseline and 24 +/- 3 hours was pre-specified. Assessments were added for suspected neurological change.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypotension Within 72 Hours</measure>
    <time_frame>From randomization through 72 hours from randomization</time_frame>
    <description>Hypotension (abnormally low blood pressure) was the most likely adverse event that could be associated with the study treatment, and is the primary basis (risk) on which neurological deterioration or other untoward effects of the study treatment could occur. It is therefore examined as a numerically-measured occurrence in addition to monitoring patients closely for neurological deterioration or other symptoms. Hypotension, when named as an adverse event, was defined as the syndrome of low blood pressure with SBP &lt; 85 mmHg. Instances of hypotension were to be avoided through close monitoring, and administration of fluid bolus for SBP &lt; 110 mmHg. If hypotension did occur, it was to be reversed as quickly as possible through discontinuation of intravenous nicardipine and intravenous fluid administration, which can be accomplished readily in a variety of settings where patients with intracerebral hemorrhage are routinely housed during early hospitalization.</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment-related Serious Adverse Event Within 72 Hours of Randomization</measure>
    <time_frame>From randomization through 72 hours (3 days)</time_frame>
    <description>Adverse events (AEs) and serious adverse events (SAEs) were assessed by the site investigators for all patients, including for their potential relatedness to the study treatment. An Independent Oversight Committee (IOC) reviewed and adjudicated all adverse event data. The 72-hours-from-randomization time window was considered the most likely time frame during which treatment-related adverse events or serious adverse events would be observed. Terminology from the Medical Dictionary for Regulatory Activities (MedDRA) and severity criteria from the Common Terminology Criteria for Adverse Events (CTCAE v. 4.03) were used as a basis for reporting adverse events. Serious adverse events are defined as being fatal, life-threatening, resulting in hospitalization or prolonged hospitalization, resulting in disability or congenital anomaly, or requiring intervention to prevent permanent impairment or damage and were required to be reported promptly.</description>
  </other_outcome>
  <other_outcome>
    <measure>Any Serious Adverse Event Within the 90-day Study Period</measure>
    <time_frame>From randomization through the 90 day visit (90 ± 14 days per protocol window; up to ± 30 days data is used) or until known death, withdrawal, or loss to follow-up.</time_frame>
    <description>The complete count of all subjects who experienced any serious adverse events throughout their participation in the trial was included in this tabulation. Adverse events (AEs) and serious adverse events (SAEs) were assessed by the site investigators for all patients. Potential relatedness to the study treatment was a required reporting element for all adverse events but was not considered in this count. Terminology from the Medical Dictionary for Regulatory Activities (MedDRA) and severity criteria from the Common Terminology Criteria for Adverse Events (CTCAE v. 4.03) were used as a basis for reporting adverse events. Serious adverse events are defined as being fatal, life-threatening, resulting in hospitalization or prolonged hospitalization, resulting in disability or congenital anomaly, or requiring intervention to prevent permanent impairment or damage and were required to be reported promptly. An Independent Oversight Committee (IOC) reviewed and adjudicated adverse event data.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1000</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Standard SBP Reduction Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous nicardipine hydrochloride will be used as necessary (pro re nata or &quot;PRN&quot;) as the primary agent in lowering SBP.
The goal for the standard BP reduction group will be to reduce and maintain SBP &lt; 180 mmHg for 24 hours from randomization. 160 mmHg is the target SBP for this arm.
For the standard group, SBP below the assigned treatment range is not artificially elevated to stay within the range if lower SBP occurs with nicardipine turned off (no fluid bolus given unless SBP falls below 110 mmHg with nicardipine off and there is risk for hypotension). Euvolemic fluid maintenance is encouraged for all patients according to their medical needs, which may differ.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive SBP Reduction Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous nicardipine hydrochloride will be used as necessary (pro re nata or &quot;PRN&quot;) as the primary agent in lowering SBP.
The goal for the intensive BP reduction group will be to reduce and maintain SBP &lt; 140 mmHg for 24 hours from randomization. 125 mmHg is the target SBP for this arm.
For the intensive group, SBP falling below 110 mmHg (lower limit of the assigned treatment range) with nicardipine off is treated with normal saline fluid bolus to prevent or remedy hypotension. Euvolemic fluid maintenance is encouraged for all patients according to their medical needs, which may differ.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous nicardipine hydrochloride</intervention_name>
    <description>IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range.
Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present.</description>
    <arm_group_label>Standard SBP Reduction Arm</arm_group_label>
    <arm_group_label>Intensive SBP Reduction Arm</arm_group_label>
    <other_name>Cardene® I.V.</other_name>
    <other_name>Nicardipine HCl injection</other_name>
    <other_name>nicardipine hydrochloride injection</other_name>
    <other_name>nicardipine IV</other_name>
    <other_name>nicardipine</other_name>
    <other_name>nicardipine hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  IV nicardipine can be initiated within 4.5 hours of symptom onset.

          -  Clinical signs consistent with the diagnosis of stroke, including impairment of
             language, motor function, cognition, and/or gaze, vision, or neglect.

          -  Total Glasgow Coma Scale (GCS) score (aggregate of verbal, eye, and motor response
             scores) of 5 or greater at time of emergency department (ED) arrival.

          -  International normalized ratio (INR) value &lt; 1.5

          -  CT scan demonstrates intraparenchymal hematoma with manual hematoma volume measurement
             &lt;60 cc.

          -  For subjects randomized prior to IV antihypertensive administration: SBP greater than
             180 mmHg* prior to IV antihypertensive treatment (this includes pre-hospital
             treatment) AND WITHOUT spontaneous SBP reduction to below 180 mmHg at the time of
             randomization OR

          -  For subjects randomized after IV antihypertensive administration: SBP greater than 180
             mmHg* prior to IV antihypertensive treatment (this includes pre-hospital treatment)
             AND WITHOUT SBP reduction to below 140 mmHg at the time of randomization.

          -  Informed consent obtained by subject, legally authorized representative, or next of
             kin.

               -  Notes: The unit &quot;mmHg&quot; stands for &quot;millimeters of mercury&quot;, a standard way of
                  measuring blood pressure. Patients with SBP &lt; 180 mmHg should be monitored for
                  4.5 hours from symptom onset as their SBP may rise to eligible levels before the
                  eligibility window closes.

        Exclusion Criteria:

          -  ICH is due to previously known neoplasms, arteriovenous malformation (AVM), or
             aneurysms.

          -  Intracerebral hematoma considered to be related to trauma.

          -  ICH located in infratentorial regions such as pons or cerebellum.

          -  Intraventricular hemorrhage (IVH) associated with intraparenchymal hemorrhage and
             blood completely fills one lateral ventricle or more than half of both ventricles.

          -  Patient to receive immediate surgical evacuation.

          -  Current pregnancy, or parturition within previous 30 days, or active lactation.

          -  Use of dabigatran within the last 48 hours**.

          -  A platelet count less than 50,000 per microliter (µL or mm3)

          -  Known sensitivity to nicardipine.

          -  Pre-morbid disability requiring assistance in ambulation or activities of daily
             living.

          -  Subject's living will precludes aggressive ICU management.

          -  Subject is currently participating in another interventional clinical trial

               -  Use of dabigatran was clarified through investigator presentations, educational
                  materials, and clinical tools to include newer similar class medications (such as
                  rivaroxaban, apixaban, and edoxaban) that were being developed and in various
                  stages of approval across enrolling countries through the course of this trial,
                  in the event that patients using these medications may have been encountered
                  during screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adnan I Qureshi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuko Y Palesch, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan I Qureshi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuko Y Palesch, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Comprehensive Stroke Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maricopa Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Pheonix</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner University Medical Center - South Campus</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <zip>85713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner University Medical Center - University Campus</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Regional Medical Center of Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Regan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-9574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Roseville Medical Center</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Clara Valley Medical Center</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Neurological Institute</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale - New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida, Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Idaho Medical Consultants</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF Saint Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University Memorial Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62794-9643</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lutheran Hospital Indiana</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkview Hospital</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Jefferson Medical Center</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interim LSU Hospital</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center, Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>South Portland</city>
        <state>Maine</state>
        <zip>04106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University - Detroit Receiving Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai-Grace Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegiance Health</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essentia Health St. Mary's Medical Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Southdale Hospital</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Cloud Hospital</name>
      <address>
        <city>St. Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regions Hospital</name>
      <address>
        <city>St.Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Neuroscience Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Regional Medical Center</name>
      <address>
        <city>Clifton</city>
        <state>New Jersey</state>
        <zip>07012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Neuroscience Institute, JFK Medical Center</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08818</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York City Health and Hospitals Corp. / Kings County Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mamoides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sister of Charity/Buffalo Mercy Hospital, Catholic Health System</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHS Wilson Medical Center</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <zip>13790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lincoln Medical and Mental Health Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strong Stroke Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801-4601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guilford Neurologic Associates</name>
      <address>
        <city>Greenboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vidant Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Clinical Research Institute/Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center (Wake Forest School of Medicine)</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron General Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University - Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toledo Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Health Sciences Center (OUHSC)</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Brain and Spine Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Univ/ Hershey Med Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hahnemann University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC-Mercy Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reading Hospital</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellspan York Hospital</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Health</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Stroke Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seton Medical Center Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. David's Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Brackenridge</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern - Parkland Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Baptist Medical Center</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <zip>78550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Herman - Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Ben Taub Community Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - St. Luke's Episcopal Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital - The Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University - Ruby Memorial Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwakee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>2E3.27WMC</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang City</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan City</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baotou Central Hospital</name>
      <address>
        <city>Baotou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Datong Third People's Hospital</name>
      <address>
        <city>Datong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan City</city>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Taizhou</name>
      <address>
        <city>Taizhou City</city>
        <zip>318020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Fourth Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300140</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Brain Hospital</name>
      <address>
        <city>Wuhan</city>
        <zip>430019</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>People's Hopital of Zhengzhou</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universtity Medicine Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Frankfurt Hoechst</name>
      <address>
        <city>Frankfurt</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Halle</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Meunster</name>
      <address>
        <city>Munster</city>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tubingen</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya Medical Center</name>
      <address>
        <city>Nagoya City</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakamura Memorial Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8570</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohamashi Tobu Hospital</name>
      <address>
        <city>Kanagawa</city>
        <state>Kanagowa</state>
        <zip>230-8765</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Kumamoto Hospital</name>
      <address>
        <city>Kumamoto City</city>
        <state>Kumamoto</state>
        <zip>861-4193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu Medical Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu University Hospital</name>
      <address>
        <city>Gifu</city>
        <zip>501-1194</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marianna - Toyoko</name>
      <address>
        <city>Kawasaki</city>
        <zip>211-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marianna University Hospital</name>
      <address>
        <city>Kawasaki</city>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Kobe City</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawasaki Medical School</name>
      <address>
        <city>Okayama</city>
        <zip>701-0192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cerebral and Cardiovascular Center</name>
      <address>
        <city>Osaka</city>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kohnan Hospital</name>
      <address>
        <city>Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Central Hospital - Tokyo</name>
      <address>
        <city>Tokyo</city>
        <zip>108-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyorin University</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Boramae Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hopital</name>
      <address>
        <city>Taichung City</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shin-Kong Wu Ho-Su Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>111</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veteran's Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://drive.google.com/file/d/0B4XP2p9l3yybYk1sX2pBYm1LSFh1cEZndHoySkVQZUxJN2Jz/view?usp=sharing</url>
    <description>Study protocol</description>
  </link>
  <reference>
    <citation>Qureshi AI, Palesch YY, Martin R, Novitzke J, Cruz-Flores S, Ehtisham A, Ezzeddine MA, Goldstein JN, Hussein HM, Suri MF, Tariq N; Antihypertensive Treatment of Acute Cerebral Hemorrhage Study Investigators. Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study. Arch Neurol. 2010 May;67(5):570-6. doi: 10.1001/archneurol.2010.61.</citation>
    <PMID>20457956</PMID>
  </reference>
  <reference>
    <citation>Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) investigators. Antihypertensive treatment of acute cerebral hemorrhage. Crit Care Med. 2010 Feb;38(2):637-48. doi: 10.1097/CCM.0b013e3181b9e1a5.</citation>
    <PMID>19770736</PMID>
  </reference>
  <reference>
    <citation>Qureshi AI. Acute hypertensive response in patients with stroke: pathophysiology and management. Circulation. 2008 Jul 8;118(2):176-87. doi: 10.1161/CIRCULATIONAHA.107.723874. Review.</citation>
    <PMID>18606927</PMID>
  </reference>
  <reference>
    <citation>Qureshi AI. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH): rationale and design. Neurocrit Care. 2007;6(1):56-66.</citation>
    <PMID>17356194</PMID>
  </reference>
  <reference>
    <citation>Qureshi AI, Palesch YY. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: design, methods, and rationale. Neurocrit Care. 2011 Dec;15(3):559-76. doi: 10.1007/s12028-011-9538-3.</citation>
    <PMID>21626077</PMID>
  </reference>
  <reference>
    <citation>Qureshi AI, Palesch YY, Martin R, Novitzke J, Cruz Flores S, Ehtisham A, Goldstein JN, Kirmani JF, Hussein HM, Suri MF, Tariq N; Antihypertensive Treatment of Acute Cerebral Hemorrhage Investigators. Systolic blood pressure reduction and risk of acute renal injury in patients with intracerebral hemorrhage. Am J Med. 2012 Jul;125(7):718.e1-6. doi: 10.1016/j.amjmed.2011.09.031. Epub 2012 May 4.</citation>
    <PMID>22560810</PMID>
  </reference>
  <reference>
    <citation>Qureshi AI, Palesch YY, Martin R, Toyoda K, Yamamoto H, Wang Y, Wang Y, Hsu CY, Yoon BW, Steiner T, Butcher K, Hanley DF, Suarez JI. Interpretation and Implementation of Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT II). J Vasc Interv Neurol. 2014 Jun;7(2):34-40.</citation>
    <PMID>25132910</PMID>
  </reference>
  <results_reference>
    <citation>Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, Moy CS, Silbergleit R, Steiner T, Suarez JI, Toyoda K, Wang Y, Yamamoto H, Yoon BW; ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network. Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. N Engl J Med. 2016 Sep 15;375(11):1033-43. doi: 10.1056/NEJMoa1603460. Epub 2016 Jun 8.</citation>
    <PMID>27276234</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2010</study_first_submitted>
  <study_first_submitted_qc>August 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2010</study_first_posted>
  <results_first_submitted>January 1, 2017</results_first_submitted>
  <results_first_submitted_qc>March 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2017</results_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute hypertensive response</keyword>
  <keyword>intracerebral hemorrhage</keyword>
  <keyword>blood pressure</keyword>
  <keyword>outcome</keyword>
  <keyword>nicardipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Nicardipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A public use data set from the study database will be made available. A process for sharing subject head imaging studies that may be associated with the data set is under evaluation.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>Protocol</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://drive.google.com/file/d/0B4XP2p9l3yybYk1sX2pBYm1LSFh1cEZndHoySkVQZUxJN2Jz/view?usp=sharing</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 8,532 patients who presented to enrolling sites for emergency care within 6 hours of symptom onset and were found to have non-traumatic intracerebral hemorrhage (ICH) on head CT imaging were screened for eligibility beginning January 7, 2011. A total of 1000 patients were enrolled in the trial between May 15, 2011 and September 14, 2015.</recruitment_details>
      <pre_assignment_details>Consent for participation was obtained from the patient or their allowable representative prior to randomization. All patients randomized were considered as enrolled. Treatment to lower systolic blood pressure (SBP) to the assigned range had to begin within 4.5 hours from symptom onset. Treatment for elevated SBP was not delayed for randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard SBP Reduction Arm</title>
          <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the standard blood pressure reduction group was to reduce and maintain SBP under 180 mmHg for 24 hours from randomization. The target SBP for this treatment arm was approximately 160 mmHg (the center of the assigned treatment group range of SBP 140-179 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater then the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was to be decreased incrementally or was discontinued if SBP fell below the assigned treatment range.</description>
        </group>
        <group group_id="P2">
          <title>Intensive SBP Reduction Arm</title>
          <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the intensive blood pressure reduction group was to reduce and maintain SBP under 140 mmHg for 24 hours from randomization. The target SBP for this treatment arm was 125 mmHg (the center of the treatment group range SBP 110 - 139 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP after infusion of the maximum nicardipine dose for 30 min, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was decreased incrementally or was discontinued if SBP fell below the assigned treatment range. Fluid bolus was given if needed for hypotension.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="500"/>
                <participants group_id="P2" count="500"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="480"/>
                <participants group_id="P2" count="481"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Analyzed (any other reason)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects were randomized to standard vs. intensive SBP control. Below-range SBP was not artifically elevated in the standard SBP reduction arm; euvolemic fluid balance was maintained but spontaneous recovery was not prevented. For below-range SBP in the intensive SBP control arm, nicardipine was discontinued and if needed IV fluid bolus was given.</population>
      <group_list>
        <group group_id="B1">
          <title>Standard SBP Reduction Arm</title>
          <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the standard blood pressure reduction group was to reduce and maintain SBP under 180 mmHg for 24 hours from randomization. The target SBP for this treatment arm was approximately 160 mmHg (the center of the assigned treatment group range of SBP 140-179 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was to be decreased incrementally or was discontinued if SBP fell below the assigned treatment range.</description>
        </group>
        <group group_id="B2">
          <title>Intensive SBP Reduction Arm</title>
          <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the intensive blood pressure reduction group was to reduce and maintain SBP under 140 mmHg for 24 hours from randomization. The target SBP for this treatment arm was 125 mmHg (the center of the treatment group range SBP 110 - 139 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP after infusion of the maximum nicardipine dose for 30 min, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was decreased incrementally or was discontinued if SBP fell below the assigned treatment range. Fluid bolus was given if needed for hypotension.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="500"/>
            <count group_id="B2" value="500"/>
            <count group_id="B3" value="1000"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" spread="13.1"/>
                    <measurement group_id="B2" value="62" spread="13.1"/>
                    <measurement group_id="B3" value="61.93" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="380"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="316"/>
                    <measurement group_id="B2" value="304"/>
                    <measurement group_id="B3" value="620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>Ethnicity describes persons who have (versus have not) self-identified as being of Cuban, Mexican, Puerto Rican, Cuban, South or Central American, or other Spanish culture or origin, regardless of race.
Data are analyzed according to the ethnicity and race of patients included to determine whether there are population differences in health measures or treatment responses that differ. Whether recruitment included an adequate diversity within the affected population is important to understanding the generalizability of results that were obtained and whether further research may be indicated.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="446"/>
                    <measurement group_id="B2" value="446"/>
                    <measurement group_id="B3" value="892"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race and ethnicity were recorded according to how a person identified themselves, not according to genetic testing or observation. The number of persons who reported American Indian, Alaska Native, Native Hawaiian of other Pacific Islander, or of having origins within more than one race has been included in the &quot;other or unknown&quot; category because the number of persons enrolled in the study from each of these categories was too small to provide a meaningful analysis that would examine these groups individually. Asian race included patients enrolled in Asian countries and non-Asian countries.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="277"/>
                    <measurement group_id="B3" value="562"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="287"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other or unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Recruited at site in Asia</title>
          <description>Defined as patients who were enrolled at a clinical site geographically located within regions including Japan, China, Taiwan, or South Korea. Data from these patients were analyzed separately in addition to being part of the full group and other race/ethnicity analyses to examine for potential population differences surrounding intracerebral hemorrhage (ICH) events and recovery that are regional in nature.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="273"/>
                    <measurement group_id="B2" value="264"/>
                    <measurement group_id="B3" value="537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>First Glasgow Coma Scale Score assessed upon hospital emergency department (ED) arrival</title>
          <description>The Glasgow Coma Scale (GCS) score is a measure of level of consciousness. The scale quantifies response in three components: eye, motor, and verbal. A lower score indicates a reduced response and a higher score indicates a full response. At least one point is given in each category so the scale ranges from 3 to 15. A score of 3 indicates deep unconsciousness; a higher score indicates milder impairment of consciousness. The maximum score of 15 indicates consciousness is not impaired but other neurological symptoms may still be present. Estimated verbal scoring was used for intubated patients.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>ED arrival GCS score = 3 - 11</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ED arrival GCS score = 12 - 14</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="294"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ED arrival GCS score = 15</title>
                  <measurement_list>
                    <measurement group_id="B1" value="284"/>
                    <measurement group_id="B2" value="275"/>
                    <measurement group_id="B3" value="559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure at presentation in hospital emergency department (ED)</title>
          <description>Blood pressure is reported as the systolic (systolic blood pressure or &quot;SBP&quot;) reading &quot;over&quot; the diastolic (or DBP) reading, and is measured in millimeters of mercury (mmHg) on a gauge. SBP is a measure of the force pressing against the blood vessels when the heart contracts to push blood out to the body, and was considered most important for this study. DBP measures lingering pressure within the blood vessels as the heart fills with newly-oxygenated blood from the lungs. Hospitals selected the method that they felt was the most accurate way to report systolic blood pressures for each patient.</description>
          <population>Data were missing for 1 patient in the standard-treatment group. It was permissible for pre-arrival or post-admission qualifying SBP to be used in eligibility determination if all other criteria were met.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="499"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="999"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201.1" spread="26.9"/>
                    <measurement group_id="B2" value="200" spread="27.1"/>
                    <measurement group_id="B3" value="200.6" spread="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median NIHSS score (range)</title>
          <description>The National Institutes of Health Stroke Scale (NIHSS) is a serial measure of neurologic deficit (problems in function). It uses a scale (range 0 - 42) to quantify neurologic deficits in 11 categories. The categories are measured by asking questions that indicate the patient's level of consciousness, then testing horizontal eye movements, visual fields, facial palsy, movement in each limb, sensation, language and speech, and extinction or inattention on one side of the body. A score of 0 indicates normal function without neurologic deficit. Higher scores indicate greater severity of deficit.</description>
          <units>units on a scale (NIHSS range 0 - 42)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11" lower_limit="0" upper_limit="40"/>
                    <measurement group_id="B2" value="11" lower_limit="0" upper_limit="40"/>
                    <measurement group_id="B3" value="11" lower_limit="0" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intracerebral Hematoma Volume</title>
          <description>Hematoma volumes are reported in cubic centimeters (cm3), as measured by the central reader. The area of the hematoma on head CT imaging was delineated by image analysis software with the use of density thresholds on each slice, followed by manual correction. The central reader and those performing manual correction were unaware of the patient identities, treatment assignments, clinical findings, and time points of image acquisition. The software provided total volume measurements by summing up volumes (product of area and slice thickness) from all the slices containing the hematoma.</description>
          <population>A precise measure of bleeding within the brain was occasionally unable to be determined or baseline imaging wasn't submitted for analysis before data lock. This measure was missing for 8 patients in the standard treatment group and 4 in the intensive group. For eligibility, hematoma volume was estimated rapidly in 3 dimensions (ABC/2) at bedside.</population>
          <units>cubic centimeters (cm3)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="496"/>
                    <count group_id="B3" value="988"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.2" lower_limit="0.98" upper_limit="79.1"/>
                    <measurement group_id="B2" value="10.3" lower_limit="2.3" upper_limit="85.2"/>
                    <measurement group_id="B3" value="10.3" lower_limit="0.98" upper_limit="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intracerebral hematoma volume greater than 30 cm3</title>
          <description>Hematoma volumes are reported in cubic centimeters (cm3), as measured by the central reader. The area of the hematoma on head CT imaging was delineated by image analysis software with the use of density thresholds on each slice, followed by manual correction. The central reader and those performing manual correction were unaware of the patient identities, treatment assignments, clinical findings, and time points of image acquisition. The software provided total volume measurements by summing up volumes (product of area and slice thickness) from all the slices containing the hematoma.</description>
          <population>A precise measure of bleeding within the brain was occasionally unable to be determined or baseline imaging wasn't submitted for analysis before data lock. This measure was missing for 8 patients in the standard treatment group and 4 in the intensive group. For eligibility, hematoma volume was estimated rapidly in 3 dimensions (ABC/2) at bedside.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="496"/>
                    <count group_id="B3" value="988"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraventricular Hemorrhage</title>
          <description>Intraventricular hemorrhage is bleeding that is present within the ventricles, or internal fluid-filled spaces, within the brain. These spaces are usually filled with cerebrospinal fluid that also circulates around the brain and spinal column, which helps to protect and cushion the delicate brain tissue. In this study, when intraventricular hemorrhage was present it meant that bleeding had extended from another region within the brain tissue to also being present in the brain ventricles. Intraventricular blood is associated with other complications and may indicate a more severe condition.</description>
          <population>The presence of blood within a brain ventricle as opposed to the hematoma (blood clot) within surrounding brain tissue pressing in to the ventricular space occasionally can't be determined, or baseline imaging wasn't submitted for analysis. This measure was missing for 8 patients in the standard treatment group and 4 in the intensive group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="496"/>
                    <count group_id="B3" value="988"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location of Hemorrhage</title>
          <description>The primary location of hemorrhage (bleeding) in the brain tissue was recorded as being located in the basal ganglia, thalamus, or a lobar region on either the right or left side of the brain. One patient was included that had a cerebellar hemorrhage, which means that bleeding was in the lower dorsal (back) region of the brain.</description>
          <population>The primary location of bleeding within the brain is occasionally unable to be clearly determined, or baseline imaging wasn't submitted for analysis. This measure was missing for 8 patients in the standard treatment group and 4 in the intensive group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="492"/>
                    <count group_id="B2" value="496"/>
                    <count group_id="B3" value="988"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Thalamus</title>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="193"/>
                    <measurement group_id="B3" value="373"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Basal ganglia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                    <measurement group_id="B2" value="255"/>
                    <measurement group_id="B3" value="506"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cerebral lobe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cerebellum</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior stroke/transient ischemic attack</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Other prior nervous system disorders</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of congestive heart failure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of atrial fibrillation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Myocardial infarction in the previous 3 months</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of coronary artery disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="382"/>
                    <measurement group_id="B2" value="411"/>
                    <measurement group_id="B3" value="793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of peripheral vascular disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of hyperlipidemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of cardiac dysrhythmias</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of diabetes mellitus Type 2</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous use of antihypertensive drugs</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="235"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symptom onset to randomization time, minutes</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="184.7" spread="56.7"/>
                    <measurement group_id="B2" value="182.2" spread="57.2"/>
                    <measurement group_id="B3" value="183.5" spread="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symptom onset to nicardipine infusion time</title>
          <description>To qualify, patients had to have SBP greater than 180 mmHg prior to antihypertensive treatment and SBP not below 140 mmHg at the time of randomization. Nicardipine infusion had to be able to start within 4.5 hours of symptom onset. In accordance with recommendations, treatment of significant hypertension in patients presenting with ICH was not delayed for consent and randomization. This measure captures the earliest nicardipine start time but other intravenous antihypertensive medications may have been given before then. &quot;Zero&quot; nicardipine start rates may not have been recorded in all cases.</description>
          <population>Data from 24 (3 intensive and 21 standard arm) patients was missing. If nicardipine wasn't needed to achieve the assigned SBP range at the time of randomization, more common in the standard arm, nicardipine was initiated at zero rate. &quot;Zero rate&quot; IV infusions have less consistent recording. Some patients had SBP within range without nicardipine.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="479"/>
                    <count group_id="B2" value="497"/>
                    <count group_id="B3" value="976"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.3" spread="101.3"/>
                    <measurement group_id="B2" value="149" spread="65"/>
                    <measurement group_id="B3" value="157" spread="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean minimum systolic blood pressure, during the first 2 hours post randomization</title>
          <population>Data were missing for 3 subjects in the standard treatment arm. If a vasoactive IV drip medication (such as nicardipine) is not in use, then standard-of-care parameters for close monitoring of SBP are different (frequency of required monitoring is less). Patient transfer and some procedures can preclude vigilance in recording research-only SBP.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="497"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="997"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141.1" spread="14.8"/>
                    <measurement group_id="B2" value="128.9" spread="16"/>
                    <measurement group_id="B3" value="135" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Failure to attain systolic blood pressure target within 2 hours</title>
          <description>Elevation of systolic blood pressure is common with intracerebral hemorrhage. Recovery of normalized blood pressure may occur quickly for some patients and only after an extended time for others, and more or less medication may be needed. The systolic blood pressure goal is usually achieved incrementally, as antihypertensive medication begins to take effect to control blood pressure. A lower target SBP range may take longer or be more difficult to achieve. The goal in this study was to achieve blood pressure control within 2 hours of randomization for all patients, regardless of treatment arm.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Failure to attain systolic blood pressure target for 2 consecutive hours during 2-24 hours</title>
          <description>This data parameter is a measure of the success (or lack of success) with which SBP control to the assigned treatment range was consistently maintained during the 24-hour SBP control study period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="500"/>
                    <count group_id="B2" value="500"/>
                    <count group_id="B3" value="1000"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Death or Disability According to Modified Rankin Scale Score at 90 Days (3 Months) From Randomization</title>
        <description>The primary outcome was death or disability, defined by modified Rankin scale (mRS) of 4-6 at 90 days following treatment. The modified Rankin Scale score ranges from 0, indicating no symptoms, to 6, indicating death. A score of 4 indicates moderately severe disability including the inability to walk or attend to one's own bodily needs. A score of 5 indicates severe disability; bedridden, incontinent, and requiring constant nursing care. To score a 3 or lower on the mRS, a person must at least be able to walk without the assistance of another person. We chose the mRS because of its high inter-observer reliability, superiority to other indices, and consistency with previous trials in patients with ICH. Reliability was further increased by use of a structured interview template and by requiring mRS assessors to pass a certification test. Persons conducting the 90-day mRS assessment were to be unaware of the treatment arm or clinical course of the patients they assessed.</description>
        <time_frame>90 days (± 14 days per protocol window; up to ± 30 days data is used) from randomization</time_frame>
        <population>All subjects were analyzed for known death at any time following randomization. Patients surviving through 90 days (± 14 days per protocol window; data used up to ± 30 days) were assessed for disability using the mRS. Patients not completing the 90-day visit within 30 days of due date aren't included in the death &amp; disability participant counts.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard SBP Reduction Arm</title>
            <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the standard blood pressure reduction group was to reduce and maintain SBP under 180 mmHg for 24 hours from randomization. The target SBP for this treatment arm was approximately 160 mmHg (the center of the assigned treatment group range of SBP 140-179 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was to be decreased incrementally or was discontinued if SBP fell below the assigned treatment range.</description>
          </group>
          <group group_id="O2">
            <title>Intensive SBP Reduction Arm</title>
            <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the intensive blood pressure reduction group was to reduce and maintain SBP under 140 mmHg for 24 hours from randomization. The target SBP for this treatment arm was 125 mmHg (the center of the treatment group range SBP 110 - 139 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP after infusion of the maximum nicardipine dose for 30 min, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was decreased incrementally or was discontinued if SBP fell below the assigned treatment range. Fluid bolus was given if needed for hypotension.</description>
          </group>
        </group_list>
        <measure>
          <title>Death or Disability According to Modified Rankin Scale Score at 90 Days (3 Months) From Randomization</title>
          <description>The primary outcome was death or disability, defined by modified Rankin scale (mRS) of 4-6 at 90 days following treatment. The modified Rankin Scale score ranges from 0, indicating no symptoms, to 6, indicating death. A score of 4 indicates moderately severe disability including the inability to walk or attend to one's own bodily needs. A score of 5 indicates severe disability; bedridden, incontinent, and requiring constant nursing care. To score a 3 or lower on the mRS, a person must at least be able to walk without the assistance of another person. We chose the mRS because of its high inter-observer reliability, superiority to other indices, and consistency with previous trials in patients with ICH. Reliability was further increased by use of a structured interview template and by requiring mRS assessors to pass a certification test. Persons conducting the 90-day mRS assessment were to be unaware of the treatment arm or clinical course of the patients they assessed.</description>
          <population>All subjects were analyzed for known death at any time following randomization. Patients surviving through 90 days (± 14 days per protocol window; data used up to ± 30 days) were assessed for disability using the mRS. Patients not completing the 90-day visit within 30 days of due date aren't included in the death &amp; disability participant counts.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death or disability at 90 days (mRS = 4 - 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                    <measurement group_id="O2" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Known death at or before 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life at 90 Days Using EuroQol (EQ) Measures: EQ-5D (EuroQol Five Dimension), Consisting of Standardized EQ-5D-3L (EuroQol Five Dimension, Three-Level) Questionnaire and EQ VAS (EuroQol Visual Analog Scale) Scores</title>
        <description>Standardized scales developed by the EuroQol Research Foundation were used as a secondary outcome measure in addition to the mRS scale score. The EQ-5D is a simple, standardized non-disease-specific instrument for describing and valuating health-related quality of life. The EQ-5D-3L questionnaire consists of 5 questions in 5 different domains and allows for responses from 1 (the best outcome) to 3 (the worst outcome) in each of five categories (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Total scores range from 5 to 15, with lower scores indicating better quality of life and a higher score indicating a worse quality of life. A second component of EuroQol outcome measurements is a printed 20 cm visual analogue scale (EQ VAS) that appears somewhat like a thermometer, on which a score from 0 (worst imaginable health state or death) to 100 (best imaginable health state) is marked by the patient (or, when necessary, their proxy) with the scale in view.</description>
        <time_frame>90 days (± 14 days per protocol window; up to ± 30 days data is used) from randomization</time_frame>
        <population>All available valid data were analyzed. Outcomes collected outside of 90 ± 30 days weren't considered valid. EQ-5D data were missing for 28 patients in the intensive group &amp; for 27 in the standard group. EQ VAS data were missing for 144 patients in the intensive group and for 146 in the standard group.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard SBP Reduction Arm</title>
            <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the standard blood pressure reduction group was to reduce and maintain SBP under 180 mmHg for 24 hours from randomization. The target SBP for this treatment arm was approximately 160 mmHg (the center of the assigned treatment group range of SBP 140-179 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was to be decreased incrementally or was discontinued if SBP fell below the assigned treatment range.</description>
          </group>
          <group group_id="O2">
            <title>Intensive SBP Reduction Arm</title>
            <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the intensive blood pressure reduction group was to reduce and maintain SBP under 140 mmHg for 24 hours from randomization. The target SBP for this treatment arm was 125 mmHg (the center of the treatment group range SBP 110 - 139 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP after infusion of the maximum nicardipine dose for 30 min, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was decreased incrementally or was discontinued if SBP fell below the assigned treatment range. Fluid bolus was given if needed for hypotension.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life at 90 Days Using EuroQol (EQ) Measures: EQ-5D (EuroQol Five Dimension), Consisting of Standardized EQ-5D-3L (EuroQol Five Dimension, Three-Level) Questionnaire and EQ VAS (EuroQol Visual Analog Scale) Scores</title>
          <description>Standardized scales developed by the EuroQol Research Foundation were used as a secondary outcome measure in addition to the mRS scale score. The EQ-5D is a simple, standardized non-disease-specific instrument for describing and valuating health-related quality of life. The EQ-5D-3L questionnaire consists of 5 questions in 5 different domains and allows for responses from 1 (the best outcome) to 3 (the worst outcome) in each of five categories (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Total scores range from 5 to 15, with lower scores indicating better quality of life and a higher score indicating a worse quality of life. A second component of EuroQol outcome measurements is a printed 20 cm visual analogue scale (EQ VAS) that appears somewhat like a thermometer, on which a score from 0 (worst imaginable health state or death) to 100 (best imaginable health state) is marked by the patient (or, when necessary, their proxy) with the scale in view.</description>
          <population>All available valid data were analyzed. Outcomes collected outside of 90 ± 30 days weren't considered valid. EQ-5D data were missing for 28 patients in the intensive group &amp; for 27 in the standard group. EQ VAS data were missing for 144 patients in the intensive group and for 146 in the standard group.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="473"/>
                <count group_id="O2" value="472"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EQ-5D utility scale questionnaire</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="473"/>
                    <count group_id="O2" value="472"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.7" lower_limit="-0.109" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ VAS (visual analog scale)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="354"/>
                    <count group_id="O2" value="356"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="62.5" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematoma Expansion (Number of Patients With Hematoma Expansion of 33% or Greater Between the Baseline and 24 +/- 6 Hours Head CTs, as Measured by the Central Reader for Patients With Readable Scans for Both Time Points Submitted by Data Lock.)</title>
        <description>Hematoma expansion as determined by serial CT scans: Hematoma expansion was defined as an increase in the volume of intraparenchymal hemorrhage of 33% or greater as measured by a central imaging analyst who was was unaware of the treatment assignments, clinical findings, and time points of image acquisition. The area of the hematoma was delineated by image analysis software with the use of density thresholds on each slice, followed by manual correction. To ensure accuracy and consistency of the readings, images were coded randomly and independently of subject numbers and manual correction was also done without awareness of treatment assignments, clinical findings, or time points of image acquisition. This data point is defined as being present (hematoma expansion of 33% or more was calculated between the baseline scan hematoma volume and the 24 +/- 6 hours hematoma volume measures at data analysis), meaning that hematoma expansion as defined must have occurred or it was not counted.</description>
        <time_frame>From the baseline head CT to the 24 +/- 6 hours from randomization head CT</time_frame>
        <population>Participants with readable head CTs at baseline and 24 +/- 6 hours from randomization (submitted before data lock) were analyzed. Hematoma expansion was only recorded as present if ≥ 33% volume increase was calculated. Scans done outside of time window + margin, submitted after data lock, or not readable in standard DICOM format could not be used.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard SBP Reduction Arm</title>
            <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the standard blood pressure reduction group was to reduce and maintain SBP under 180 mmHg for 24 hours from randomization. The target SBP for this treatment arm was approximately 160 mmHg (the center of the assigned treatment group range of SBP 140-179 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was to be decreased incrementally or was discontinued if SBP fell below the assigned treatment range.</description>
          </group>
          <group group_id="O2">
            <title>Intensive SBP Reduction Arm</title>
            <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the intensive blood pressure reduction group was to reduce and maintain SBP under 140 mmHg for 24 hours from randomization. The target SBP for this treatment arm was 125 mmHg (the center of the treatment group range SBP 110 - 139 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP after infusion of the maximum nicardipine dose for 30 min, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was decreased incrementally or was discontinued if SBP fell below the assigned treatment range. Fluid bolus was given if needed for hypotension.</description>
          </group>
        </group_list>
        <measure>
          <title>Hematoma Expansion (Number of Patients With Hematoma Expansion of 33% or Greater Between the Baseline and 24 +/- 6 Hours Head CTs, as Measured by the Central Reader for Patients With Readable Scans for Both Time Points Submitted by Data Lock.)</title>
          <description>Hematoma expansion as determined by serial CT scans: Hematoma expansion was defined as an increase in the volume of intraparenchymal hemorrhage of 33% or greater as measured by a central imaging analyst who was was unaware of the treatment assignments, clinical findings, and time points of image acquisition. The area of the hematoma was delineated by image analysis software with the use of density thresholds on each slice, followed by manual correction. To ensure accuracy and consistency of the readings, images were coded randomly and independently of subject numbers and manual correction was also done without awareness of treatment assignments, clinical findings, or time points of image acquisition. This data point is defined as being present (hematoma expansion of 33% or more was calculated between the baseline scan hematoma volume and the 24 +/- 6 hours hematoma volume measures at data analysis), meaning that hematoma expansion as defined must have occurred or it was not counted.</description>
          <population>Participants with readable head CTs at baseline and 24 +/- 6 hours from randomization (submitted before data lock) were analyzed. Hematoma expansion was only recorded as present if ≥ 33% volume increase was calculated. Scans done outside of time window + margin, submitted after data lock, or not readable in standard DICOM format could not be used.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="450"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Neurological Deterioration Within 24 Hours, Defined by a Decrease of 2 or More Points on the GCS Score or an Increase of 4 or More Points on the NIHSS Score From Baseline, Not Related to Sedation or Hypnotic-agent Use and Sustained for at Least 8 Hours.</title>
        <description>Neurologic deterioration was measured using two scales. The Glasgow Coma Scale (GCS) score measures of level of consciousness in eye, motor, and verbal components. At least one point is given in each category. The scale ranges from 3 to 15, with 3 indicating deep unconsciousness and 15 indicating consciousness is not impaired. The National Institutes of Health Stroke Scale (NIHSS) quantifies neurologic deficits in 11 categories. Level of consciousness, horizontal eye movement, visual fields, facial palsy, movement in each limb, sensation, language &amp; speech, and extinction or inattention on one side of the body are tested. Scores range from 0 to 42, with 0 indicating normal function and higher scores indicating greater deficit severity. Neurological status was checked per ICU standards through 24 hours, recommended as hourly GCS and full assessment every 2 hours. NIHSS assessment at baseline and 24 +/- 3 hours was pre-specified. Assessments were added for suspected neurological change.</description>
        <time_frame>From randomization through the 24-hour treatment period</time_frame>
        <population>All subjects were assessed for neurological status regularly. Grid-estimated verbal scoring based on eye and motor scores was used for intubated patients so that GCS scores could be compared over time and was consistent across patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard SBP Reduction Arm</title>
            <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the standard blood pressure reduction group was to reduce and maintain SBP under 180 mmHg for 24 hours from randomization. The target SBP for this treatment arm was approximately 160 mmHg (the center of the assigned treatment group range of SBP 140-179 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was to be decreased incrementally or was discontinued if SBP fell below the assigned treatment range.</description>
          </group>
          <group group_id="O2">
            <title>Intensive SBP Reduction Arm</title>
            <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the intensive blood pressure reduction group was to reduce and maintain SBP under 140 mmHg for 24 hours from randomization. The target SBP for this treatment arm was 125 mmHg (the center of the treatment group range SBP 110 - 139 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP after infusion of the maximum nicardipine dose for 30 min, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was decreased incrementally or was discontinued if SBP fell below the assigned treatment range. Fluid bolus was given if needed for hypotension.</description>
          </group>
        </group_list>
        <measure>
          <title>Neurological Deterioration Within 24 Hours, Defined by a Decrease of 2 or More Points on the GCS Score or an Increase of 4 or More Points on the NIHSS Score From Baseline, Not Related to Sedation or Hypnotic-agent Use and Sustained for at Least 8 Hours.</title>
          <description>Neurologic deterioration was measured using two scales. The Glasgow Coma Scale (GCS) score measures of level of consciousness in eye, motor, and verbal components. At least one point is given in each category. The scale ranges from 3 to 15, with 3 indicating deep unconsciousness and 15 indicating consciousness is not impaired. The National Institutes of Health Stroke Scale (NIHSS) quantifies neurologic deficits in 11 categories. Level of consciousness, horizontal eye movement, visual fields, facial palsy, movement in each limb, sensation, language &amp; speech, and extinction or inattention on one side of the body are tested. Scores range from 0 to 42, with 0 indicating normal function and higher scores indicating greater deficit severity. Neurological status was checked per ICU standards through 24 hours, recommended as hourly GCS and full assessment every 2 hours. NIHSS assessment at baseline and 24 +/- 3 hours was pre-specified. Assessments were added for suspected neurological change.</description>
          <population>All subjects were assessed for neurological status regularly. Grid-estimated verbal scoring based on eye and motor scores was used for intubated patients so that GCS scores could be compared over time and was consistent across patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hypotension Within 72 Hours</title>
        <description>Hypotension (abnormally low blood pressure) was the most likely adverse event that could be associated with the study treatment, and is the primary basis (risk) on which neurological deterioration or other untoward effects of the study treatment could occur. It is therefore examined as a numerically-measured occurrence in addition to monitoring patients closely for neurological deterioration or other symptoms. Hypotension, when named as an adverse event, was defined as the syndrome of low blood pressure with SBP &lt; 85 mmHg. Instances of hypotension were to be avoided through close monitoring, and administration of fluid bolus for SBP &lt; 110 mmHg. If hypotension did occur, it was to be reversed as quickly as possible through discontinuation of intravenous nicardipine and intravenous fluid administration, which can be accomplished readily in a variety of settings where patients with intracerebral hemorrhage are routinely housed during early hospitalization.</description>
        <time_frame>From randomization through 72 hours from randomization</time_frame>
        <population>Blood pressure including the potential for hypotension was monitored according to intensive care unit standards for ICH patients during early hospitalization. Blood pressure was monitored more closely during the 24-hour study period and at times when nicardipine (or other/secondary IV antihypertensive medications) were being titrated.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard SBP Reduction Arm</title>
            <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the standard blood pressure reduction group was to reduce and maintain SBP under 180 mmHg for 24 hours from randomization. The target SBP for this treatment arm was approximately 160 mmHg (the center of the assigned treatment group range of SBP 140-179 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was to be decreased incrementally or was discontinued if SBP fell below the assigned treatment range.</description>
          </group>
          <group group_id="O2">
            <title>Intensive SBP Reduction Arm</title>
            <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the intensive blood pressure reduction group was to reduce and maintain SBP under 140 mmHg for 24 hours from randomization. The target SBP for this treatment arm was 125 mmHg (the center of the treatment group range SBP 110 - 139 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP after infusion of the maximum nicardipine dose for 30 min, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was decreased incrementally or was discontinued if SBP fell below the assigned treatment range. Fluid bolus was given if needed for hypotension.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypotension Within 72 Hours</title>
          <description>Hypotension (abnormally low blood pressure) was the most likely adverse event that could be associated with the study treatment, and is the primary basis (risk) on which neurological deterioration or other untoward effects of the study treatment could occur. It is therefore examined as a numerically-measured occurrence in addition to monitoring patients closely for neurological deterioration or other symptoms. Hypotension, when named as an adverse event, was defined as the syndrome of low blood pressure with SBP &lt; 85 mmHg. Instances of hypotension were to be avoided through close monitoring, and administration of fluid bolus for SBP &lt; 110 mmHg. If hypotension did occur, it was to be reversed as quickly as possible through discontinuation of intravenous nicardipine and intravenous fluid administration, which can be accomplished readily in a variety of settings where patients with intracerebral hemorrhage are routinely housed during early hospitalization.</description>
          <population>Blood pressure including the potential for hypotension was monitored according to intensive care unit standards for ICH patients during early hospitalization. Blood pressure was monitored more closely during the 24-hour study period and at times when nicardipine (or other/secondary IV antihypertensive medications) were being titrated.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Treatment-related Serious Adverse Event Within 72 Hours of Randomization</title>
        <description>Adverse events (AEs) and serious adverse events (SAEs) were assessed by the site investigators for all patients, including for their potential relatedness to the study treatment. An Independent Oversight Committee (IOC) reviewed and adjudicated all adverse event data. The 72-hours-from-randomization time window was considered the most likely time frame during which treatment-related adverse events or serious adverse events would be observed. Terminology from the Medical Dictionary for Regulatory Activities (MedDRA) and severity criteria from the Common Terminology Criteria for Adverse Events (CTCAE v. 4.03) were used as a basis for reporting adverse events. Serious adverse events are defined as being fatal, life-threatening, resulting in hospitalization or prolonged hospitalization, resulting in disability or congenital anomaly, or requiring intervention to prevent permanent impairment or damage and were required to be reported promptly.</description>
        <time_frame>From randomization through 72 hours (3 days)</time_frame>
        <population>Relatedness is defined by the terms unrelated, unlikely, possibly, probably, or definitely related to the study treatment. Results are entered as the count of participants experiencing any serious adverse event within 72 hours of randomization that was determined by the site investigator to possibly or more have relationship to the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard SBP Reduction Arm</title>
            <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the standard blood pressure reduction group was to reduce and maintain SBP under 180 mmHg for 24 hours from randomization. The target SBP for this treatment arm was approximately 160 mmHg (the center of the assigned treatment group range of SBP 140-179 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was to be decreased incrementally or was discontinued if SBP fell below the assigned treatment range.</description>
          </group>
          <group group_id="O2">
            <title>Intensive SBP Reduction Arm</title>
            <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the intensive blood pressure reduction group was to reduce and maintain SBP under 140 mmHg for 24 hours from randomization. The target SBP for this treatment arm was 125 mmHg (the center of the treatment group range SBP 110 - 139 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP after infusion of the maximum nicardipine dose for 30 min, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was decreased incrementally or was discontinued if SBP fell below the assigned treatment range. Fluid bolus was given if needed for hypotension.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Serious Adverse Event Within 72 Hours of Randomization</title>
          <description>Adverse events (AEs) and serious adverse events (SAEs) were assessed by the site investigators for all patients, including for their potential relatedness to the study treatment. An Independent Oversight Committee (IOC) reviewed and adjudicated all adverse event data. The 72-hours-from-randomization time window was considered the most likely time frame during which treatment-related adverse events or serious adverse events would be observed. Terminology from the Medical Dictionary for Regulatory Activities (MedDRA) and severity criteria from the Common Terminology Criteria for Adverse Events (CTCAE v. 4.03) were used as a basis for reporting adverse events. Serious adverse events are defined as being fatal, life-threatening, resulting in hospitalization or prolonged hospitalization, resulting in disability or congenital anomaly, or requiring intervention to prevent permanent impairment or damage and were required to be reported promptly.</description>
          <population>Relatedness is defined by the terms unrelated, unlikely, possibly, probably, or definitely related to the study treatment. Results are entered as the count of participants experiencing any serious adverse event within 72 hours of randomization that was determined by the site investigator to possibly or more have relationship to the study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Any Serious Adverse Event Within the 90-day Study Period</title>
        <description>The complete count of all subjects who experienced any serious adverse events throughout their participation in the trial was included in this tabulation. Adverse events (AEs) and serious adverse events (SAEs) were assessed by the site investigators for all patients. Potential relatedness to the study treatment was a required reporting element for all adverse events but was not considered in this count. Terminology from the Medical Dictionary for Regulatory Activities (MedDRA) and severity criteria from the Common Terminology Criteria for Adverse Events (CTCAE v. 4.03) were used as a basis for reporting adverse events. Serious adverse events are defined as being fatal, life-threatening, resulting in hospitalization or prolonged hospitalization, resulting in disability or congenital anomaly, or requiring intervention to prevent permanent impairment or damage and were required to be reported promptly. An Independent Oversight Committee (IOC) reviewed and adjudicated adverse event data.</description>
        <time_frame>From randomization through the 90 day visit (90 ± 14 days per protocol window; up to ± 30 days data is used) or until known death, withdrawal, or loss to follow-up.</time_frame>
        <population>Patients may have experienced more than one adverse event. This measure is designed to show the total count of any patients who experienced any type of serious adverse event, whether it was felt to be related to the study treatment or not, throughout the duration of their participation in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard SBP Reduction Arm</title>
            <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the standard blood pressure reduction group was to reduce and maintain SBP under 180 mmHg for 24 hours from randomization. The target SBP for this treatment arm was approximately 160 mmHg (the center of the assigned treatment group range of SBP 140-179 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was to be decreased incrementally or was discontinued if SBP fell below the assigned treatment range.</description>
          </group>
          <group group_id="O2">
            <title>Intensive SBP Reduction Arm</title>
            <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the intensive blood pressure reduction group was to reduce and maintain SBP under 140 mmHg for 24 hours from randomization. The target SBP for this treatment arm was 125 mmHg (the center of the treatment group range SBP 110 - 139 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP after infusion of the maximum nicardipine dose for 30 min, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was decreased incrementally or was discontinued if SBP fell below the assigned treatment range. Fluid bolus was given if needed for hypotension.</description>
          </group>
        </group_list>
        <measure>
          <title>Any Serious Adverse Event Within the 90-day Study Period</title>
          <description>The complete count of all subjects who experienced any serious adverse events throughout their participation in the trial was included in this tabulation. Adverse events (AEs) and serious adverse events (SAEs) were assessed by the site investigators for all patients. Potential relatedness to the study treatment was a required reporting element for all adverse events but was not considered in this count. Terminology from the Medical Dictionary for Regulatory Activities (MedDRA) and severity criteria from the Common Terminology Criteria for Adverse Events (CTCAE v. 4.03) were used as a basis for reporting adverse events. Serious adverse events are defined as being fatal, life-threatening, resulting in hospitalization or prolonged hospitalization, resulting in disability or congenital anomaly, or requiring intervention to prevent permanent impairment or damage and were required to be reported promptly. An Independent Oversight Committee (IOC) reviewed and adjudicated adverse event data.</description>
          <population>Patients may have experienced more than one adverse event. This measure is designed to show the total count of any patients who experienced any type of serious adverse event, whether it was felt to be related to the study treatment or not, throughout the duration of their participation in the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected between randomization and the end-of-study visit. All adverse events (defined as abnormal test results, new diagnoses, worsening of conditions, or other health events of clinical significance) were collected through day 7 or hospital discharge, whichever came first. Only serious adverse events (SAEs) were collected from Day 7 (or discharge, if sooner) through final study visits at 3-months +/- 30 days. SAEs, 5-day reporting timeline.</time_frame>
      <desc>Adverse events during hospitalization: assessed from medical records. Post-hospital discharge, patients/proxy were asked if illness or hospitalization had occurred; available medical records also checked. CTCAE v. 4.03 as severity grading reference. Relatedness of adverse events: assessed by the site investigator within categories unrelated, unlikely, possibly, probably, or definitely related to the study treatment. Analyses by code + related safety groupings. AEs ≩ all subjects being affected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard SBP Reduction Arm</title>
          <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the standard blood pressure reduction group was to reduce and maintain SBP under 180 mmHg for 24 hours from randomization. The target SBP for this treatment arm was approximately 160 mmHg (the center of the assigned treatment group range of SBP 140-179 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was to be decreased incrementally or was discontinued if SBP fell below the assigned treatment range.</description>
        </group>
        <group group_id="E2">
          <title>Intensive SBP Reduction Arm</title>
          <description>Nicardipine hydrochloride was used according to need as the primary agent in lowering systolic blood pressure (SBP).
The goal for the intensive blood pressure reduction group was to reduce and maintain SBP under 140 mmHg for 24 hours from randomization. The target SBP for this treatment arm was 125 mmHg (the center of the treatment group range SBP 110 - 139 mmHg).
Nicardipine hydrochloride: IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached.
If SBP was greater than the target SBP after infusion of the maximum nicardipine dose for 30 min, a second agent could be used (Labetalol 5-20 mg IV bolus every 15 min; urapidil substituted in countries without labetalol available) for another hour. Nicardipine use was decreased incrementally or was discontinued if SBP fell below the assigned treatment range. Fluid bolus was given if needed for hypotension.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Angiopathy</sub_title>
                <description>Coded under vascular disorders, also analyzed with cardiac disorders for safety</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>(Meeting SAE criteria); coded under general disorders, also analyzed with cardiac disorders for safety</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>(Meeting SAE criteria); coded under general disorders, also analyzed with cardiac disorders for safety</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <description>Coded under vascular disorders, also analyzed with cardiac disorders for safety</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <description>Coded under vascular disorders, also analyzed with cardiac disorders for safety</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>(Meeting SAE criteria); coded under vascular disorders, also analyzed with cardiac disorders for safety</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Necrotising colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cyst aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Respiratory rate increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>CNS ventriculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="500"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Haemorrhagic infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <description>Coded under vascular disorders, also analyzed with brain infarct/nervous disorders for safety</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Neurological decompensation</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="500"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Stroke in evolution</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Subdural hygroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Schizophrenia, paranoid type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <description>Coded under investigations, also analyzed with renal disorders for safety</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="500"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cranioplasty</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Subdural haematoma evacuation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <description>(Meeting SAE criteria)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="500" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="500" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <description>Coded under vascular disorders, also analyzed with cardiac disorders for safety</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic increased</sub_title>
                <description>Coded under investigations, also analyzed with cardiac disorders for safety</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <description>Coded under investigations, also analyzed with cardiac disorders for safety</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>(AE Not meeting SAE criteria); coded under general disorders, also analyzed with cardiac disorders for safety</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST segment depression</sub_title>
                <description>Coded under investigations, also analyzed with cardiac disorders for safety</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>(AE Not meeting SAE criteria); coded under vascular disorders, also analyzed with cardiac disorders for safety</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>(AE Not meeting SAE criteria); coded under vascular disorders, also analyzed with cardiac disorders for safety</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="500"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ventricular hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Retinal degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Retinopathy hypertensive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Scleral oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="500"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="500"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Stress ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="500"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="40" subjects_affected="39" subjects_at_risk="500"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dacryocystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Enterocolitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="500"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="500"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="500"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Urinary tract infection fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Post transfusion purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood chloride abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood chloride increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Coma scale abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Gastric occult blood positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Monocyte count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>PO2 decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Procalcitonin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sputum culture positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Streptococcus test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkalosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hyperchloraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hyperhomocysteinaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypermagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="500"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="500"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="500"/>
                <counts group_id="E2" events="39" subjects_affected="38" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="500"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="500"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Vitamin B12 deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Consciousness fluctuating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="500"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>IIIrd nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Neurological decompensation</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pneumocephalus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Seizure like phenomena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Vasogenic cerebral oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="500"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Delirium tremens</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine abnormal</sub_title>
                <description>Coded under investigations, also analyzed with renal disorders for safety</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood creatinine decreased</sub_title>
                <description>Coded under investigations, also analyzed with renal disorders for safety</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <description>(AE Not meeting SAE criteria) Coded under investigations, also analyzed with renal disorders for safety.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood urea decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate increased</sub_title>
                <description>Coded under investigations, also analyzed with renal disorders for safety</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <description>Coded under metabolism and nutrition disorders, also analyzed with renal disorders for safety</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <description>Coded under metabolism and nutrition disorders, also analyzed with renal disorders for safety</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Renal function test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="500"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Generalised erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Craniotomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Endotracheal intubation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Gastrostomy tube insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Stereotactic surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Axillary vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <description>(AE Not meeting SAE criteria)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="500"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The overall Principal Investigator IS, but the Data Coordination Unit (statistical) Principal Investigator IS NOT employed by the sponsor. Prior to release of a public-use data set, any study PIs/other collaborators may submit a proposal requesting data access, assistance with statistical analyses, and publication of additional results. All proposals are reviewed by a Publications Committee that includes the primary study PI, the statistical PI, the NINDS project scientist, and appointed others.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Treatment failures, randomization window, demographics, pre-randomization treatment, low death/disability, favorable baselines, and early termination could limit generalizability of primary (all with intent-to-treat) results and some sub-analyses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Adnan I. Qureshi, MD</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-624-2431</phone>
      <email>qureshai@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

